A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients

Trial Profile

A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Faecal incontinence
  • Focus Therapeutic Use
  • Sponsors RDD Pharma
  • Most Recent Events

    • 05 Jul 2017 According to an RDD Pharma media release, the European Medicines Agency's Committee has granted orphan designation for RDD-0315, an investigational drug for the treatment of fecal incontinence in patients with spinal cord injury.
    • 24 May 2016 Primary endpoint (The number of fecal incontinence episodes in 12 hours post drug administration) has been met according to the results presented at the Digestive Disease Week 2016.
    • 24 May 2016 Results assessing the effect of oxymetazoline on fecal incontinence presented at the Digestive Disease Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top